Reduced rates of antimicrobial resistance in Staphylococcus intermedius group and Escherichia coli isolated from diseased companion animals in an animal hospital after restriction of antimicrobial use

The 2016 National Action Plan aims for reduction in antimicrobial resistance (AMR) to tetracyclines, third-generation cephalosporins, and fluoroquinolones in Escherichia coli isolates from livestock: to lower the tetracycline resistance of E. coli to 33% or less; to maintain the third-generation cephalosporin resistance of E. coli at the same level as in the other G7 countries as of 2020; and to maintain the fluoroquinolone resistance of E. coli at the same level as in the other G7 countries as of 2020. A relatively unexplored facet of reducing AMR is the impact of minimizing transmission of AMR strains by companion animals. In this study we compared AMR rates in Staphylococcus intermedius group (SIG) and E. coli isolated from diseased companion animals in an animal hospital before and after restriction of antimicrobial use. Our study spanned a 4.5-year period from 2014 to June 2018 during which antimicrobial use was restricted in 2016. During this period, abundance of methicillin-resistant SIG isolates from the hospital dropped from 41.5% to 9.3%, and that of extended-spectrum β-lactamase (ESBL)-producing E. coli isolates dropped from 29.5% to 9.5%. Tests for antimicrobial susceptibility revealed significantly reduced rates of AMR to enrofloxacin and levofloxacin in SIG isolates, and to cefazolin in E. coli isolates after antimicrobial use was restricted. Our observations suggest that restriction of antimicrobial use, especially that of third-generation cephalosporins and fluoroquinolones, is an effective method for reducing AMR rates. These findings will be relevant in guiding antimicrobial restriction approaches in other animal hospitals and clinics.